This week, there will be no ordinary Weekly, as I have caught a persistent infection over the weekend. As I do not want to publish any copy-and-paste garbage, I decided to skip an episode after more than three years non-stop. But …
Continue reading
Investing in stocks of companies that went bankrupt, seriously? Seriously! What at first sounds like a recipe for disaster, indeed can be a lucrative endeavor. A bankrupt company is not the same as the ceasing of operations. Indeed, often it is even the case that companies go into bankruptcy restructuring while everyday operations continue. This area can be a great treasure trove to fish for potential multi-baggers where others don’t bother due to negative associations. A premier on Financial Engineering: My Premium PLUS members receive my latest stock idea – a pick that recently emerged from bankruptcy – with the potential to multi-bag.
Continue reading
In the spotlight today is the Western European market leader in the frozen food industry. With a portfolio of multiple brands, the company’s roots span over a century. The current setup was formed in 2015, when the brands Iglo and Findus were acquired. Since the IPO, a decade has passed, yet the stock is trading (again) where it had started. Are a near 5% dividend yield and a PE ratio of 7 enough to spark appetite, or is something fishy?
Continue reading
It’s been three years (and a month) since I launched Financial-Engineering.net in August 2022 to share my unfiltered thoughts on stocks, their valuations, risks like dividend cuts, and my best ideas that survive my rigorous research process. In past anniversary posts, I’ve offered food-for-thought insights. Today, I’m cracking the myth of “safe” stocks.
Continue reading
In May 2024, I published a Weekly about gold mining stocks. My focus was on how to analyze them, and which parameters to know and watch. I also compared the industry’s three biggest names to evaluate how they performed, and why so (at that time, they had, surprisingly for many, underperformed the spot gold price). Today, I discuss three gold miners I like from a quality perspective for the watchlist. All my members on top will receive my latest stock idea – a gold stock, but with a slightly different case. Even if the gold price does not rise, this could become a multi-bagger which is unlikely for most gold stocks.
Continue reading
Though initially not planned as a trilogy in that sense, today I am taking a closer look at Diageo, the world’s biggest spirits company. Like its competitors Pernod Ricard and Brown-Foreman, Diageo stock has nosedived, and caused strong headaches for its investors. After the stock got cut in half, while the broader market ran from high to high, the question arises, whether this could be a good contrarian pick right now. Especially with the dividend now being on a historically high level.
Continue reading
When I go through the comments below YouTube videos where I appeared, the feedback is overall positive or neutral if the commenter has a different opinion. Of course that’s perfectly fine, everyone shall express their views. Occasionally, I find comments where I am described as having a negative attitude, being bearish or overly pessimistic. While I don’t care on a personal level in the sense that I do not feel offended or take such comments personally, one such comment has led me to think about it a bit deeper – and write a Weekly about it! While it sounds contradictory at first sight, it simply fits into my investment and analysis approach.
Continue reading
Is AI the biggest bubble we have ever witnessed? There are many voices claiming so, while others are of the view mankind has reached a new plateau in its evolution. As this is not a new topic per se, and my skepticism is well-known among my readers, I am not going to drill deeper on this front. However, there is a subtopic that deserves much more attention than it actually gets. Maybe because it is so boring and likely ahead of its time, the majority currently does not care. I do, though. And you probably should either.
Continue reading
Many investors seek “moats”, or key differentiators that keep competitors at a distance. These “high-quality stocks” not seldom trade at premium valuations. At least for as long as this superior status is perceived. One such edge can be a brand. Well-known names create a barrier which in the best case even keeps new entrants out of the game entirely. However, it is no secret that brands come and go. Are we seeing another washout where once thought-to-be indispensable names are struggling for a reason? All my paid members receive my latest stock idea. It is a company with a strong market position where the brand name is irrelevant, for most even unknown.
Continue reading
Biotech stocks are known for two things: either being graveyards for shareholders’ money or generating outsized returns – especially if they become multi-baggers (assuming one is positioned before the retail crowd discovers such ideas). While not every biotech stock turns out to be a do-or-die binary bet, it is safe to say that those stocks with big moves catch much attention – no matter the direction. Sarepta Therapeutics is such a case. It has even offered its shareholders both, an astronomical rise and a fall from grace despite generating billion-USD sales. A case study worth to have heard of.
Continue reading